(Q38058385)

27 August 2017

title

Effect of darunavir on lipid profile in HIV-infected patients (English)

1 reference

27 August 2017

1 reference

Edgar Turner Overton

1

1 reference

27 August 2017

Eduardo Arathoon

series ordinal

2

1 reference

27 August 2017

Ezio Baraldi

series ordinal

3

1 reference

27 August 2017

Frank Tomaka

series ordinal

4

1 reference

27 August 2017

publication date

1 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

13

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

256-270

1 reference

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Tolerability and safety of HIV protease inhibitors in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Impact of HIV infection and HAART on serum lipids in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Biomarkers and HIV-associated cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Dyslipidemia in the era of HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Insulin Resistance and the cardiometabolic syndrome in HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Elevated triglycerides and risk of myocardial infarction in HIV-positive persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Protease inhibitors and cardiovascular outcomes in patients with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1305-256

21 January 2018

Identifiers

DOI

10.1310/HCT1305-256

1 reference

27 August 2017

1 reference